top of page
Fidelion Diagnostics is pioneering a new era of predictive oncology. We are developing a revolutionary, AI-driven platform to provide life-saving insights for cancer patients and physicians worldwide. Our mission is to transform cancer from a terminal disease into a manageable, survivable condition.
Redefining the Future of Cancer Survivability
Redefining the Future of Health
Our Vision:From Recurrence to Prevention
At Fidelion, we believe the future of cancer care is proactive, not reactive. Our strategy is built on two horizons:
Saving Lives
Today
We are launching the VitaGuard™ platform, a high-performance, ultra-sensitive liquid biopsy test for monitoring cancer recurrence.
By detecting molecular residual disease (MRD) months or years earlier than imaging, we empower oncologists to intervene and save lives.
Preventing Onset Tomorrow
Our cost-efficient VitaGuard™ test is also a powerful data acquisition engine. By generating the largest, richest longitudinal cancer dataset in the world, we are building a predictive AI that will one day be able to intercept cancer before it ever takes hold.
About Fidelion Diagnostics
Fidelion Diagnostics is a global biotechnology company established to commercialize the clinically validated, patented VitaGuard™ platform for cancer diagnostics. Our company is led by a seasoned team of scientific, clinical, and business experts dedicated to making our visionary "AI Survivability Engine" a reality for patients everywhere.
bottom of page